We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 499

Federal court rejects PMPRB Copaxone decision on excessive prices again

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second

Collaborating for success

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

One often hears the phrase "it takes a village." Although often used in the context of rearing children, it is equally applicable to the development

Subsequent entry biologics: a new paradigm

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

There are several biologic drugs approved for use in Canada comprising an estimated 14-16 per cent of the prescription pharmaceutical market. Health

An end to generic claims for innovator profits?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the "NOC Regulations"

Authorized generics in the hypothetical world of generic damages

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada, as in other jurisdictions, links drug marketing approval with patent rights. Innovative drug manufacturers may list relevant patents against

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

Data protection: defining innovative drug in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994

A balancing act: innovation and the regulatory-approval exemption

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In the pharmaceutical sector, patent systems are concerned with balancing the interests of innovator drug companies, the public and generic

Patented medicines (notice of compliance) listing update

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Listing a patent on the Patent Register maintained by the Minister of Health is the gateway through which an innovator gains access to the provisions

Generic ordered to pay $1.7 million in accounting of profits

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

On March 12, 2013, the Federal Court released its decision in Apotex Inc. v. H. Lundbeck AS, 2013 FC 192. The Court dismissed Apotex's action to

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy